Costco Wholesale Corporation (NASDAQ:COST): Baird raised its price target on Costco following Q3 results. The firm said the company represents a compelling growth story citing its traffic trends, potential for improved margins, and declining input costs. Shares are Outperform rated.
Human Genome Sciences Inc. (NASDAQ:HGSI): Baird said they remain confident that a higher bid for Human Genome (NASDAQ:HGSI) will emerge despite Glaxo’s (NYSE:GSK) indication it will suspend the tender offer while the company’s poison pill is in effect. The firm met with management and said their calculations point to a bid closer to $20. Shares are Outperform rated with a $19 price target.
NewLink Genetics Corp (NASDAQ:NLNK): Stifel Nicolaus is more upbeat about NewLink’s outlook after the company presented data from a trial of its HyperAcute Pancreas treatment that the firm views as positive. The firm believes that the treatment could be used for multiple tumor types and it maintains a Buy rating on the stock. .
VeriFone Systems, Inc (NYSE:PAY): Wedbush believes VeriFone management blaming their below consensus guidance on currency is contrary to previous conference calls where management said currency has an immaterial impact on results. The firm expects shares of VeriFone to struggle as management guides to higher growth rates and free cash flow falls short of reported earnings. Wedbush keeps a Neutral rating on VeriFone post the company’s Q2 results.
General Mills Inc. (NYSE:GIS): After General Mills agreed to buy Brazil’s Yoki Alimentos for $1B, Stifel Nicolaus believes that the deal provides General Mills with significant scale in an attractive market. The firm views the acquisition price as reasonable and maintains a Buy rating on General Mills.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.